Needham Maintains Buy on Cara Therapeutics, Lowers Price Target to $5

Benzinga · 01/22 22:07
Needham analyst Joseph Stringer maintains Cara Therapeutics (NASDAQ:CARA) with a Buy and lowers the price target from $6 to $5.